focus -WSS

focus

author：Wikipedia 2025-10-01 10:37:12 - browse：9

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

The Harvard botanist who searched for psychedelics in the Amazon

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Military medical care influenced by rank and race, new study finds

He's a Nobel laureate. Critics say he was misleading on Covid

Wikipedia

focus

knowledge

How one medical school became remarkably diverse

Alabama frozen embryo ruling has major implications for IVF clinics

The cancer drug shortage isn’t new — and neither are the solutions

Arc Institute generative AI designs new CRISPR systems

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Novavax promises a turnaround & Lilly roils the obesity market

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Medical records are filled with copy

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

leisure time

Alabama IVF ruling threatens families facing fatal genetic disease

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

6 phony surgeries that take placebo to the extreme

Arc Institute generative AI designs new CRISPR systems

PBM reform efforts get punted in Congress

It's time to retire 'poor historian' from clinicians' vocabularies

Wikipedia

hotspot

hotspot

entertainment